Free Trial
→ We’ve Entered the Most Bullish Phase of the Cycle (From Crypto Swap Profits) (Ad) Buy MPW Stock  Free MPW Stock Alerts

Medical Properties Trust (MPW) Financials

Medical Properties Trust logo
$4.45 +0.01 (+0.23%)
Closing price 03:59 PM Eastern
Extended Trading
$4.42 -0.03 (-0.67%)
As of 04:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Medical Properties Trust

Annual Income Statements for Medical Properties Trust

This table shows Medical Properties Trust's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 140 225 290 1,017 375 431 656 903 -556 -2,410
Consolidated Net Income / (Loss)		 140 226 291 1,018 376 432 657 904 -556 -2,408
Net Income / (Loss) Continuing Operations		 140 226 291 1,018 376 432 657 904 -556 -2,408
Total Pre-Tax Income 		140 219 294 1,019 374 463 731 960 -687 -2,364
Total Revenue		 442 541 705 785 616 921 1,177 1,543 872 996
Net Interest Income / (Expense)		 0.00 0.00 0.00 162 -238 -329 -367 0.00 0.00 0.00
Total Interest Income		 0.00 0.00 0.00 162 0.00 0.00 0.00 0.00 0.00 0.00
Total Interest Expense		 0.00 0.00 0.00 0.00 238 329 367 0.00 0.00 0.00
Total Non-Interest Income		 442 541 705 622 854 1,249 1,545 1,543 872 996
Other Service Charges		 112 108 129 - 150 142 169 166 69 49
Other Non-Interest Income		 330 433 576 622 704 1,107 1,376 1,377 803 947
Total Non-Interest Expense		 179 359 396 495 294 421 506 898 1,202 1,027
Net Occupancy & Equipment Expense		 3.79 - - - - - - 46 42 27
Other Operating Expenses		 44 211 241 314 120 157 185 520 557 552
Depreciation Expense		 70 94 125 133 152 264 321 333 603 448
Nonoperating Income / (Expense), net		 -123 37 -15 729 51 -36 60 315 -357 -2,333
Income Tax Expense		 - -6.83 2.68 0.93 -2.62 31 74 56 -131 44
Net Income / (Loss) Attributable to Noncontrolling Interest		 0.33 0.89 1.45 1.79 1.72 0.82 0.92 1.22 0.38 1.98
Basic Earnings per Share		 $0.64 $0.86 $0.82 $2.77 $0.87 $0.81 $1.11 $1.50 ($0.93) ($4.02)
Weighted Average Basic Shares Outstanding		 218.00M 260.41M 349.90M 365.36M 427.08M 529.24M 588.82M 598.63M 598.52M 600.25M
Diluted Earnings per Share		 $0.63 $0.86 $0.82 $2.76 $0.87 $0.81 $1.11 $1.50 ($0.93) ($4.02)
Weighted Average Diluted Shares Outstanding		 218.30M 261.07M 350.44M 366.27M 428.30M 530.46M 590.14M 598.84M 598.52M 600.25M
Weighted Average Basic & Diluted Shares Outstanding		 218.10M 261.70M 353.40M 367M 520.93M 580M 599.90M 598.30M 599.10M 600.60M
Cash Dividends to Common per Share		 $0.87 $0.90 $0.95 $0.99 $1.01 $1.07 $1.11 $1.15 $1.17 $0.38

Quarterly Income Statements for Medical Properties Trust

This table shows Medical Properties Trust's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 222 -140 33 -42 117 -664 -876 -321 -801 -413
Consolidated Net Income / (Loss)		 222 -140 33 -42 117 -664 -875 -320 -801 -412
Net Income / (Loss) Continuing Operations		 222 -140 33 -42 117 -664 -875 -320 -801 -412
Total Pre-Tax Income 		241 -125 37 -191 127 -660 -864 -305 -792 -403
Total Revenue		 264 469 350 337 200 -16 271 165 120 440
Net Interest Income / (Expense)		 -88 88 32 0.00 -107 75 11 -101 -106 197
Total Interest Income		 0.00 - 32 0.00 0.00 -32 11 0.00 0.00 -11
Total Interest Expense		 88 -88 0.00 0.00 107 -107 0.00 101 106 -208
Total Non-Interest Income		 352 380 318 337 307 -90 260 267 226 243
Other Non-Interest Income		 310 339 318 277 277 -69 260 250 216 220
Total Non-Interest Expense		 127 312 230 529 122 320 222 145 246 412
Other Operating Expenses		 46 185 146 165 45 201 147 43 42 320
Depreciation Expense		 82 81 84 364 78 77 76 102 205 65
Nonoperating Income / (Expense), net		 104 -286 -83 1.06 49 -324 -913 -325 -665 -430
Income Tax Expense		 19 15 3.54 -148 10 3.98 11 15 9.03 9.56
Net Income / (Loss) Attributable to Noncontrolling Interest		 0.23 0.26 0.24 -0.40 0.19 0.36 0.25 0.98 0.23 0.53
Basic Earnings per Share		 $0.37 ($0.24) $0.05 ($0.07) $0.19 ($1.10) ($1.46) ($0.54) ($1.34) ($0.68)
Weighted Average Basic Shares Outstanding		 598.98M 598.63M 598.30M 598.34M 598.44M 598.52M 600.30M 600.06M 600.23M 600.25M
Diluted Earnings per Share		 $0.37 ($0.24) $0.05 ($0.07) $0.19 ($1.10) ($1.46) ($0.54) ($1.34) ($0.68)
Weighted Average Diluted Shares Outstanding		 599.34M 598.84M 598.31M 598.34M 598.55M 598.52M 600.30M 600.06M 600.23M 600.25M
Weighted Average Basic & Diluted Shares Outstanding		 598M 598.30M 598.30M 598.40M 599M 599.10M 600.10M 600.20M 600.40M 600.60M

Annual Cash Flow Statements for Medical Properties Trust

This table details how cash moves in and out of Medical Properties Trust's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 62 -110 70 667 652 -928 -99 -207 3.02 84
Net Cash From Operating Activities		 207 264 362 449 494 618 812 739 506 245
Net Cash From Continuing Operating Activities		 207 264 362 449 499 618 812 739 506 245
Net Income / (Loss) Continuing Operations		 140 226 291 1,018 376 432 657 904 -556 -2,408
Consolidated Net Income / (Loss)		 140 226 291 1,018 376 432 657 904 -556 -2,408
Depreciation Expense		 72 98 132 141 157 276 334 346 616 454
Amortization Expense		 6.09 7.61 6.52 7.36 8.88 13 17 17 16 17
Non-Cash Adjustments to Reconcile Net Income		 -26 -76 -44 906 -95 -101 -209 -441 555 2,198
Changes in Operating Assets and Liabilities, net		 15 9.13 -24 -34 53 -2.60 13 -87 -125 -16
Net Cash From Investing Activities		 -1,946 -927 -2,362 564 -4,884 -2,947 -3,858 396 518 1,318
Net Cash From Continuing Investing Activities		 -1,946 -927 -2,362 564 -4,884 -2,947 -3,858 396 518 1,318
Purchase of Property, Leasehold Improvements and Equipment		 -146 -171 -74 - -84 -68 -68 -109 -114 -80
Purchase of Investment Securities		 -2,590 -1,911 -2,361 - -4,913 -4,348 -5,698 -1,748 -780 -682
Sale and/or Maturity of Investments		 791 1,156 73 4,181 113 1,470 1,908 2,253 1,412 2,080
Net Cash From Financing Activities		 1,801 553 2,070 -346 5,042 1,401 2,948 -1,343 -1,020 -1,479
Net Cash From Continuing Financing Activities		 1,801 553 2,070 -252 5,042 1,812 2,948 -1,343 -1,020 -1,479
Net Change in Deposits		 -11 15 28 21 -12 22 18 -5.02 10 2.24
Issuance of Debt		 1,190 1,000 2,906 760 2,983 2,379 3,968 129 568 804
Issuance of Common Equity		 817 1,174 548 188 2,533 411 1,051 0.00 0.00 0.00
Repayment of Debt		 -0.28 -1,385 -1,038 -812 0.00 -800 -1,391 -666 -988 -1,833
Repurchase of Common Equity		 - - - - - 0.00 0.00 -18 0.00 0.00
Payment of Dividends		 -183 -218 -327 364 -412 -568 -643 -699 -615 -321
Other Financing Activities, Net		 -13 -32 -46 -3.61 -50 369 -54 -84 5.18 -132
Cash Interest Paid		 214 278 150 222 211 310 326 354 406 420

Quarterly Cash Flow Statements for Medical Properties Trust

This table details how cash moves in and out of Medical Properties Trust's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 57 -80 64 6.53 30 -97 -23 384 -345 69
Net Cash From Operating Activities		 214 181 136 77 158 135 74 35 59 77
Net Cash From Continuing Operating Activities		 214 181 136 77 158 135 74 35 59 77
Net Income / (Loss) Continuing Operations		 222 -140 33 -42 117 -664 -875 -320 -801 -412
Consolidated Net Income / (Loss)		 222 -140 33 -42 117 -664 -875 -320 -801 -412
Depreciation Expense		 85 85 88 368 81 80 77 104 206 66
Amortization Expense		 3.90 3.92 4.01 4.08 3.88 3.80 3.70 3.79 4.78 5.08
Non-Cash Adjustments to Reconcile Net Income		 -100 251 29 -181 -20 727 881 308 623 386
Changes in Operating Assets and Liabilities, net		 3.02 -18 -18 -72 -23 -12 -12 -61 26 32
Net Cash From Investing Activities		 324 -462 17 392 -62 170 -119 1,202 144 92
Net Cash From Continuing Investing Activities		 324 -462 17 392 -62 170 -119 1,202 144 92
Purchase of Property, Leasehold Improvements and Equipment		 -6.62 -11 -13 -15 -52 -34 -30 -15 -18 -16
Purchase of Investment Securities		 -83 -452 -192 -250 -232 -106 -222 -289 -186 16
Sale and/or Maturity of Investments		 414 1.01 222 657 223 310 133 1,507 348 92
Net Cash From Financing Activities		 -481 201 -89 -462 -67 -403 22 -854 -548 -100
Net Cash From Continuing Financing Activities		 -481 201 -89 -462 -67 -403 22 -854 -548 -100
Net Change in Deposits		 -5.77 -2.43 -2.69 9.85 0.60 2.39 6.23 2.28 -9.23 2.96
Repayment of Debt		 -201 204 0.00 -215 -319 -454 0.00 -1,381 -401 -51
Payment of Dividends		 -174 -174 -177 -174 -174 -91 -93 -90 -90 -48
Other Financing Activities, Net		 -36 -0.63 -5.77 13 -0.72 -0.98 -2.57 -78 -48 -3.76
Cash Interest Paid		 76 68 116 111 95 84 132 123 95 71

Annual Balance Sheets for Medical Properties Trust

This table presents Medical Properties Trust's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 5,609 6,419 9,020 8,844 14,467 16,829 20,520 19,658 18,305 14,295
Cash and Due from Banks		 196 83 171 821 1,462 550 459 236 250 332
Loans and Leases, Net of Allowance		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Mortgage Servicing Rights		 758 1,060 1,778 1,213 1,275 248 213 364 309 120
Other Assets		 1,433 1,043 1,369 1,156 2,934 2,964 3,239 5,381 2,663 2,375
Total Liabilities & Shareholders' Equity		 5,609 6,419 9,020 8,844 14,467 16,829 20,520 19,658 18,305 14,295
Total Liabilities		 3,502 3,165 5,185 4,283 7,439 9,485 12,074 11,064 10,671 9,461
Long-Term Debt		 3,323 2,909 4,899 4,037 7,024 8,865 11,283 10,268 10,064 8,848
Other Long-Term Liabilities		 29 20 229 41 554 181 791 174 607 613
Total Equity & Noncontrolling Interests		 2,107 3,253 3,835 4,561 7,028 7,344 8,446 8,594 7,634 4,834
Total Preferred & Common Equity		 2,102 3,248 3,821 4,547 7,028 7,339 8,440 8,593 7,632 4,833
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 2,102 3,248 3,821 4,547 14,119 7,339 8,440 8,593 7,632 4,833
Common Stock		 2,594 3,776 4,333 4,443 14,029 7,462 8,565 8,536 8,561 8,586
Retained Earnings		 -419 -434 -486 163 83 -71 -88 116 -972 -3,659
Accumulated Other Comprehensive Income / (Loss)		 -73 -93 -26 -58 -63 -51 -37 -59 43 -94
Noncontrolling Interest		 5.00 4.85 15 14 0.11 5.33 5.48 1.57 2.27 1.05

Quarterly Balance Sheets for Medical Properties Trust

This table presents Medical Properties Trust's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 19,043 19,650 19,204 19,005 17,301 16,195 15,236
Cash and Due from Banks		 299 302 324 340 224 607 276
Loans and Leases, Net of Allowance		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Premises and Equipment, Net		 - 11,885 - - - 11,949 11,654
Mortgage Servicing Rights		 306 346 299 302 310 399 298
Intangible Assets		 11,994 - 11,882 11,727 11,401 -1,418 -1,424
Other Assets		 6,444 3,418 6,699 6,635 5,366 4,658 4,432
Total Liabilities & Shareholders' Equity		 19,043 19,650 19,204 19,005 17,301 16,195 15,236
Total Liabilities		 10,210 11,207 10,890 10,719 10,597 10,002 9,795
Other Short-Term Payables		 569 - 445 376 303 447 418
Long-Term Debt		 9,476 10,438 10,238 10,157 10,099 9,369 9,216
Other Long-Term Liabilities		 165 769 207 186 195 186 161
Total Equity & Noncontrolling Interests		 8,833 8,443 8,315 8,285 6,704 6,193 5,441
Total Preferred & Common Equity		 8,832 8,442 8,314 8,285 6,702 6,190 5,439
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 8,832 8,442 8,314 8,285 6,702 6,190 5,439
Common Stock		 8,538 8,542 8,548 8,559 8,568 8,572 8,579
Retained Earnings		 433 -25 -241 -215 -1,847 -2,348 -3,198
Accumulated Other Comprehensive Income / (Loss)		 -139 -75 6.68 -60 -19 -34 57
Noncontrolling Interest		 1.47 1.57 0.90 0.89 2.27 2.90 2.54

Annual Metrics And Ratios for Medical Properties Trust

This table displays calculated financial ratios and metrics derived from Medical Properties Trust's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 41.39% 22.46% 30.23% 11.32% -21.43% 49.34% 27.89% 31.05% -43.49% 14.19%
EBITDA Growth		 67.87% -15.80% 55.66% -1.87% 11.24% 61.61% 29.56% -1.43% -70.02% 45.73%
EBIT Growth		 84.14% -30.85% 69.54% -6.06% 11.28% 54.89% 34.34% -3.97% -151.17% 90.61%
NOPAT Growth		 84.14% -28.69% 62.91% -5.28% 12.16% 43.50% 29.42% 0.62% -138.04% 90.61%
Net Income Growth		 175.47% 61.47% 28.90% 249.71% -63.04% 14.84% 51.97% 37.58% -161.53% -333.07%
EPS Growth		 117.24% 36.51% -4.65% 236.59% -68.48% -6.90% 37.04% 35.14% -162.00% -332.26%
Operating Cash Flow Growth		 37.59% 27.46% 37.29% 23.98% 10.03% 25.00% 31.41% -8.95% -31.56% -51.47%
Free Cash Flow Firm Growth		 -148.49% 66.14% -315.65% 118.77% -1,306.17% 67.02% -72.40% 150.51% -36.59% 327.77%
Invested Capital Growth		 52.66% 13.50% 41.72% -1.55% 63.43% 15.35% 21.71% -4.39% -6.17% -22.69%
Revenue Q/Q Growth		 -16.50% 42.10% 7.91% -3.01% -30.94% 12.28% 12.52% 27.47% -35.71% 84.24%
EBITDA Q/Q Growth		 -20.00% -19.11% 69.77% -12.92% -0.49% 28.43% 4.48% -3.10% -62.20% 389.35%
EBIT Q/Q Growth		 -25.82% -29.21% 128.39% -17.61% -4.07% 40.56% 4.65% -4.25% -303.67% 92.13%
NOPAT Q/Q Growth		 -25.82% -27.00% 126.31% -20.23% -69.18% 40.19% 7.16% -6.24% -309.59% 92.12%
Net Income Q/Q Growth		 11.69% 10.18% 11.11% 0.65% -7.14% 14.80% 18.19% -27.75% -1,599.55% 9.45%
EPS Q/Q Growth		 0.00% 4.88% 9.33% 0.73% -13.86% 19.12% 15.63% -28.23% -1,228.57% 9.46%
Operating Cash Flow Q/Q Growth		 10.76% 8.53% 14.81% 1.74% 3.51% 1.43% 7.80% -6.70% -8.28% -19.31%
Free Cash Flow Firm Q/Q Growth		 23.18% -158.34% 39.41% -16.01% -105.26% 43.40% 1.93% 15.25% 4,172.58% 13.79%
Invested Capital Q/Q Growth		 -0.86% 28.40% 0.70% 0.80% 16.29% 5.23% 4.16% 3.02% -4.04% -6.65%
Profitability Metrics		 - - - - - - - - - -
EBITDA Margin		 77.20% 53.08% 63.45% 55.93% 79.19% 85.69% 86.80% 65.29% 34.64% 44.21%
EBIT Margin		 59.57% 33.64% 43.79% 36.95% 52.34% 54.29% 57.02% 41.78% -37.84% -3.11%
Profit (Net Income) Margin		 31.67% 41.75% 41.33% 129.82% 61.07% 46.96% 55.80% 58.58% -63.79% -241.91%
Tax Burden Percent		 100.00% 103.12% 99.09% 99.91% 100.70% 93.30% 89.88% 94.18% 80.97% 101.87%
Interest Burden Percent		 53.16% 120.36% 95.23% 351.62% 115.86% 92.72% 108.88% 148.88% 208.18% 7,631.82%
Effective Tax Rate		 0.00% -3.12% 0.91% 0.09% -0.70% 6.70% 10.12% 5.82% 0.00% 0.00%
Return on Invested Capital (ROIC)		 5.86% 3.24% 4.11% 3.34% 2.87% 3.08% 3.36% 3.15% -1.26% -0.14%
ROIC Less NNEP Spread (ROIC-NNEP)		 1.37% 4.47% 3.73% 19.65% 3.80% 2.65% 3.89% 5.90% -4.46% -25.38%
Return on Net Nonoperating Assets (RNNOA)		 2.16% 5.19% 4.11% 20.92% 3.63% 2.93% 4.96% 7.46% -5.59% -38.49%
Return on Equity (ROE)		 8.02% 8.43% 8.22% 24.26% 6.50% 6.02% 8.32% 10.61% -6.85% -38.63%
Cash Return on Invested Capital (CROIC)		 -35.83% -9.40% -30.42% 4.91% -45.29% -11.18% -16.23% 7.63% 5.11% 25.46%
Operating Return on Assets (OROA)		 5.64% 3.03% 4.00% 3.25% 2.77% 3.19% 3.59% 3.21% -1.74% -0.19%
Return on Assets (ROA)		 3.00% 3.76% 3.77% 11.40% 3.23% 2.76% 3.52% 4.50% -2.93% -14.78%
Return on Common Equity (ROCE)		 8.01% 8.41% 8.19% 24.18% 10.46% 8.98% 8.32% 10.60% -6.85% -38.62%
Return on Equity Simple (ROE_SIMPLE)		 6.66% 6.96% 7.62% 22.40% 5.36% 5.89% 7.78% 10.52% -7.29% -49.83%
Net Operating Profit after Tax (NOPAT)		 263 188 306 290 325 466 603 607 -231 -22
NOPAT Margin		 59.57% 34.69% 43.39% 36.92% 52.71% 50.65% 51.25% 39.35% -26.49% -2.18%
Net Nonoperating Expense Percent (NNEP)		 4.49% -1.23% 0.37% -16.31% -0.93% 0.43% -0.53% -2.75% 3.20% 25.24%
SG&A Expenses to Revenue		 0.86% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.96% 4.77% 2.74%
Operating Expenses to Revenue		 40.43% 66.36% 56.21% 63.05% 47.66% 45.71% 42.98% 58.22% 137.84% 103.11%
Earnings before Interest and Taxes (EBIT)		 263 182 309 290 323 500 671 645 -330 -31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 341 287 447 439 488 789 1,022 1,007 302 440
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.70 0.69 0.81 0.85 0.54 1.17 1.29 0.63 0.35 0.49
Price to Tangible Book Value (P/TBV)		 0.78 0.76 0.90 0.92 0.56 1.40 1.29 0.73 0.35 0.49
Price to Revenue (P/Rev)		 3.31 4.17 4.38 4.93 12.33 9.32 9.26 3.49 3.07 2.38
Price to Earnings (P/E)		 10.48 10.02 10.66 3.81 20.29 19.88 16.63 5.96 0.00 0.00
Dividend Yield		 14.31% 12.93% 11.31% 9.43% 6.94% 6.75% 6.12% 12.90% 19.71% 11.65%
Earnings Yield		 9.54% 9.98% 9.38% 26.27% 4.93% 5.03% 6.01% 16.78% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.85 0.83 0.90 0.83 0.94 1.04 1.10 0.82 0.71 0.80
Enterprise Value to Revenue (EV/Rev)		 10.40 9.40 11.11 9.05 21.36 18.36 18.46 9.99 14.33 10.94
Enterprise Value to EBITDA (EV/EBITDA)		 13.47 17.70 17.52 16.18 26.97 21.42 21.27 15.30 41.36 24.74
Enterprise Value to EBIT (EV/EBIT)		 17.46 27.94 25.38 24.49 40.80 33.82 32.38 23.91 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 17.46 27.09 25.61 24.51 40.52 36.25 36.02 25.39 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 22.20 19.28 21.62 15.81 26.64 27.36 26.78 20.86 24.70 44.36
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 16.70 0.00 0.00 0.00 10.47 13.38 2.73
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 1.58 0.89 1.28 0.89 1.00 1.21 1.34 1.19 1.32 1.83
Long-Term Debt to Equity		 1.58 0.89 1.28 0.89 1.00 1.21 1.34 1.19 1.32 1.83
Financial Leverage		 1.58 1.16 1.10 1.06 0.95 1.11 1.28 1.26 1.25 1.52
Leverage Ratio		 2.67 2.24 2.18 2.13 2.01 2.18 2.37 2.36 2.34 2.61
Compound Leverage Factor		 1.42 2.70 2.07 7.48 2.33 2.02 2.58 3.51 4.87 199.55
Debt to Total Capital		 61.19% 47.21% 56.09% 46.96% 49.98% 54.69% 57.19% 54.44% 56.87% 64.67%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 61.19% 47.21% 56.09% 46.96% 49.98% 54.69% 57.19% 54.44% 56.87% 64.67%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.09% 0.08% 0.17% 0.16% 0.00% 0.03% 0.03% 0.01% 0.01% 0.01%
Common Equity to Total Capital		 38.72% 52.71% 43.75% 52.88% 100.48% 45.27% 42.78% 45.55% 43.12% 35.32%
Debt to EBITDA		 9.74 10.13 10.96 9.20 14.39 11.24 11.04 10.19 33.32 20.10
Net Debt to EBITDA		 9.17 9.84 10.57 7.33 11.39 10.54 10.59 9.96 32.50 19.35
Long-Term Debt to EBITDA		 9.74 10.13 10.96 9.20 14.39 11.24 11.04 10.19 33.32 20.10
Debt to NOPAT		 12.62 15.50 16.02 13.94 21.62 19.02 18.70 16.91 -43.58 -408.04
Net Debt to NOPAT		 11.88 15.06 15.46 11.10 17.12 17.84 17.94 16.53 -42.50 -392.71
Long-Term Debt to NOPAT		 12.62 15.50 16.02 13.94 21.62 19.02 18.70 16.91 -43.58 -408.04
Noncontrolling Interest Sharing Ratio		 0.14% 0.18% 0.27% 0.34% -61.07% -49.30% 0.07% 0.04% 0.02% 0.03%
Liquidity Ratios		 - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1,610 -545 -2,265 425 -5,129 -1,691 -2,916 1,473 934 3,995
Operating Cash Flow to CapEx		 141.42% 154.10% 490.75% 0.00% 589.65% 903.64% 1,198.46% 676.52% 442.02% 307.67%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 -21.56 -5.14 -7.94 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 2.08 1.88 2.21 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 1.73 1.67 2.02 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.09 0.09 0.09 0.09 0.05 0.06 0.06 0.08 0.05 0.06
Fixed Asset Turnover		 0.18 0.16 0.15 0.16 0.10 0.10 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 5,430 6,163 8,734 8,598 14,052 16,209 19,728 18,863 17,698 13,682
Invested Capital Turnover		 0.10 0.09 0.09 0.09 0.05 0.06 0.07 0.08 0.05 0.06
Increase / (Decrease) in Invested Capital		 1,873 733 2,571 -136 5,454 2,157 3,519 -866 -1,165 -4,016
Enterprise Value (EV)		 4,595 5,085 7,832 7,100 13,163 16,898 21,736 15,413 12,491 10,888
Market Capitalization		 1,463 2,255 3,090 3,870 7,601 8,577 10,907 5,378 2,675 2,372
Book Value per Share		 $8.84 $10.14 $10.49 $12.46 $27.29 $13.69 $14.15 $14.37 $12.74 $8.05
Tangible Book Value per Share		 $7.86 $9.32 $9.41 $11.49 $26.21 $11.46 $14.15 $12.35 $12.74 $8.05
Total Capital		 5,430 6,163 8,734 8,598 14,052 16,209 19,728 18,863 17,698 13,682
Total Debt		 3,323 2,909 4,899 4,037 7,024 8,865 11,283 10,268 10,064 8,848
Total Long-Term Debt		 3,323 2,909 4,899 4,037 7,024 8,865 11,283 10,268 10,064 8,848
Net Debt		 3,127 2,826 4,727 3,217 5,561 8,316 10,824 10,033 9,814 8,516
Capital Expenditures (CapEx)		 146 171 74 -54 84 68 68 109 114 80
Net Nonoperating Expense (NNE)		 123 -38 15 -729 -52 34 -54 -297 325 2,387
Net Nonoperating Obligations (NNO)		 3,323 2,909 4,899 4,037 7,024 8,865 11,283 10,268 10,064 8,848
Total Depreciation and Amortization (D&A)		 78 105 139 149 165 289 351 363 632 471
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.64 $0.86 $0.82 $2.77 $0.87 $0.81 $1.11 $1.50 ($0.93) ($4.02)
Adjusted Weighted Average Basic Shares Outstanding		 218.00M 260.41M 349.90M 365.36M 427.08M 529.24M 588.82M 598.63M 598.52M 600.25M
Adjusted Diluted Earnings per Share		 $0.63 $0.86 $0.82 $2.76 $0.87 $0.81 $1.11 $1.50 ($0.93) ($4.02)
Adjusted Weighted Average Diluted Shares Outstanding		 218.30M 261.07M 350.44M 366.27M 428.30M 530.46M 590.14M 598.84M 598.52M 600.25M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.87 $0.00 $1.11 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 237.85M 320.93M 364.69M 381.08M 520.93M 580M 599.90M 598.30M 599.10M 600.60M
Normalized Net Operating Profit after Tax (NOPAT)		 227 165 335 338 241 466 603 607 -231 -22
Normalized NOPAT Margin		 51.42% 30.47% 47.56% 43.03% 39.03% 50.65% 51.25% 39.35% -26.49% -2.18%
Pre Tax Income Margin		 31.67% 40.49% 41.71% 129.94% 60.64% 50.33% 62.08% 62.20% -78.78% -237.48%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 1.36 1.52 1.83 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 1.37 1.42 1.64 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 1.00 1.31 1.64 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 1.01 1.21 1.46 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 130.77% 96.66% 112.19% -35.73% 109.38% 131.39% 97.95% 77.29% -110.66% -13.33%
Augmented Payout Ratio		 130.77% 96.66% 112.19% -35.73% 109.38% 131.39% 97.95% 79.27% -110.66% -13.33%

Quarterly Metrics And Ratios for Medical Properties Trust

This table displays calculated financial ratios and metrics derived from Medical Properties Trust's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 -10.92% 244.35% -14.54% -15.70% -24.37% -103.35% -22.53% -51.06% -40.17% 2,904.12%
EBITDA Growth		 -13.53% -11.63% -23.75% -30.50% -28.11% -202.68% -38.62% -29.25% -47.94% 139.10%
EBIT Growth		 -18.46% -15.46% -34.60% -214.03% -43.37% -314.50% -59.22% 110.38% -263.81% 108.09%
NOPAT Growth		 -20.11% -38.45% -38.23% -184.29% -43.49% -308.02% -68.39% 110.38% -224.54% 108.09%
Net Income Growth		 29.54% -167.79% -94.77% -122.33% -47.35% -373.27% -2,750.25% -653.33% -785.17% 37.86%
EPS Growth		 27.59% -168.57% -95.24% -121.88% -48.65% -358.33% -3,020.00% -671.43% -805.26% 38.18%
Operating Cash Flow Growth		 0.79% -22.66% -24.38% -53.51% -26.04% -25.22% -45.19% -53.93% -62.58% -43.37%
Free Cash Flow Firm Growth		 122.40% 129.33% 135.59% 154.74% -108.16% -4.97% 699.61% 844.25% 6,084.82% 333.94%
Invested Capital Growth		 -3.33% -4.39% -0.82% -2.38% 0.73% -6.17% -11.01% -16.12% -20.53% -22.69%
Revenue Q/Q Growth		 -33.97% 77.31% -25.26% -3.66% -40.76% -107.84% 1,830.99% -39.14% -27.58% 267.54%
EBITDA Q/Q Growth		 -13.13% 8.80% -13.75% -14.74% -10.15% -255.40% 151.56% -1.73% -33.88% 16.72%
EBIT Q/Q Growth		 -18.65% 14.32% -23.36% -259.98% 140.40% -533.01% 114.57% -59.29% -737.74% 121.40%
NOPAT Q/Q Growth		 -20.72% -10.58% 1.86% -224.00% 153.14% -429.19% 114.58% -59.29% -737.74% 121.40%
Net Income Q/Q Growth		 16.81% -163.15% 123.56% -228.47% 375.48% -667.68% -31.92% 63.48% -150.56% 48.52%
EPS Q/Q Growth		 15.63% -164.86% 120.83% -240.00% 371.43% -678.95% -32.73% 63.01% -148.15% 49.25%
Operating Cash Flow Q/Q Growth		 29.93% -15.34% -25.10% -43.58% 106.71% -14.40% -45.10% -52.57% 67.89% 29.55%
Free Cash Flow Firm Q/Q Growth		 230.18% 29.33% -72.82% 20.42% -119.42% 1,605.42% 127.13% 42.20% 23.06% 9.15%
Invested Capital Q/Q Growth		 -3.66% 3.02% 0.10% -1.74% -0.59% -4.04% -5.06% -7.39% -5.82% -6.65%
Profitability Metrics		 - - - - - - - - - -
EBITDA Margin		 85.27% 52.33% 60.38% 53.44% 81.05% 0.00% 47.84% 77.24% 70.53% 22.40%
EBIT Margin		 51.77% 33.38% 34.23% -56.83% 38.76% 0.00% 18.02% 12.05% -106.13% 6.18%
Profit (Net Income) Margin		 84.01% -29.92% 9.43% -12.58% 58.49% 0.00% -322.64% -193.58% -669.76% -93.81%
Tax Burden Percent		 92.28% 112.24% 90.31% 22.25% 92.08% 100.60% 101.27% 104.77% 101.14% 102.37%
Interest Burden Percent		 175.87% -79.88% 30.51% 99.45% 163.87% 196.62% -1,768.51% -1,533.18% 623.98% -1,483.29%
Effective Tax Rate		 7.72% 0.00% 9.69% 0.00% 7.92% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 3.10% 1.93% 2.42% -3.01% 2.63% 0.00% 0.56% 0.31% -2.43% 0.27%
ROIC Less NNEP Spread (ROIC-NNEP)		 4.06% -0.42% 1.69% -2.11% 3.10% 0.00% -8.30% -3.10% -9.78% -4.29%
Return on Net Nonoperating Assets (RNNOA)		 4.74% -0.53% 2.00% -2.50% 3.55% 0.00% -11.25% -4.18% -13.80% -6.50%
Return on Equity (ROE)		 7.84% 1.39% 4.41% -5.51% 6.19% 0.00% -10.69% -3.88% -16.22% -6.23%
Cash Return on Invested Capital (CROIC)		 6.86% 7.63% 3.45% 3.22% -0.12% 5.11% 10.08% 16.75% 21.21% 25.46%
Operating Return on Assets (OROA)		 3.23% 2.56% 2.57% -4.15% 2.76% 0.00% 0.77% 0.42% -3.35% 0.38%
Return on Assets (ROA)		 5.25% -2.30% 0.71% -0.92% 4.17% 0.00% -13.85% -6.79% -21.14% -5.73%
Return on Common Equity (ROCE)		 7.84% 1.39% 6.68% -5.51% 6.19% 0.00% -10.69% -3.88% -16.22% -6.23%
Return on Equity Simple (ROE_SIMPLE)		 14.16% 0.00% 3.61% 0.87% -0.40% 0.00% -21.85% -28.14% -48.90% 0.00%
Net Operating Profit after Tax (NOPAT)		 126 113 108 -134 71 -235 34 14 -89 19
NOPAT Margin		 47.77% 24.09% 30.91% -39.78% 35.69% 0.00% 12.61% 8.44% -74.29% 4.32%
Net Nonoperating Expense Percent (NNEP)		 -0.96% 2.35% 0.73% -0.90% -0.46% 4.22% 8.86% 3.40% 7.35% 4.56%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 48.23% 66.62% 65.77% 156.83% 61.24% 0.00% 81.98% 87.95% 206.13% 93.82%
Earnings before Interest and Taxes (EBIT)		 137 156 120 -192 77 -335 49 20 -127 27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 225 245 211 180 162 -252 130 128 84 98
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.66 0.63 0.50 0.60 0.35 0.35 0.40 0.42 0.65 0.49
Price to Tangible Book Value (P/TBV)		 0.00 0.73 0.50 0.00 0.00 0.35 0.00 0.34 0.51 0.49
Price to Revenue (P/Rev)		 4.80 3.49 2.87 3.49 2.17 3.07 3.35 4.17 6.50 2.38
Price to Earnings (P/E)		 4.65 5.96 14.03 68.74 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 11.86% 12.90% 16.29% 14.01% 20.79% 19.71% 19.86% 13.92% 9.06% 11.65%
Earnings Yield		 21.51% 16.78% 7.13% 1.45% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.82 0.82 0.76 0.80 0.69 0.71 0.75 0.73 0.85 0.80
Enterprise Value to Revenue (EV/Rev)		 12.38 9.99 9.71 10.47 9.41 14.33 15.80 18.29 23.05 10.94
Enterprise Value to EBITDA (EV/EBITDA)		 14.42 15.30 15.29 17.24 15.96 41.36 56.87 67.73 138.47 24.74
Enterprise Value to EBIT (EV/EBIT)		 22.26 23.91 24.77 67.19 78.74 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 23.14 25.39 28.91 98.01 115.76 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 18.92 20.86 20.71 24.49 23.13 24.70 28.19 28.15 40.94 44.36
Enterprise Value to Free Cash Flow (EV/FCFF)		 11.73 10.47 22.01 24.61 0.00 13.38 6.97 3.97 3.55 2.73
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 1.07 1.19 1.24 1.23 1.23 1.32 1.51 1.51 1.69 1.83
Long-Term Debt to Equity		 1.07 1.19 1.24 1.23 1.23 1.32 1.51 1.51 1.69 1.83
Financial Leverage		 1.17 1.26 1.18 1.19 1.15 1.25 1.36 1.35 1.41 1.52
Leverage Ratio		 2.25 2.36 2.27 2.27 2.22 2.34 2.44 2.44 2.49 2.61
Compound Leverage Factor		 3.96 -1.88 0.69 2.25 3.64 4.60 -43.14 -37.41 15.57 -38.78
Debt to Total Capital		 51.76% 54.44% 55.28% 55.18% 55.07% 56.87% 60.10% 60.20% 62.88% 64.67%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 51.76% 54.44% 55.28% 55.18% 55.07% 56.87% 60.10% 60.20% 62.88% 64.67%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.01% 0.01% 0.01% 0.00% 0.00% 0.01% 0.01% 0.02% 0.02% 0.01%
Common Equity to Total Capital		 48.24% 45.55% 44.71% 44.81% 44.92% 43.12% 39.89% 39.78% 37.11% 35.32%
Debt to EBITDA		 9.12 10.19 11.09 11.87 12.71 33.32 45.83 55.90 102.47 20.10
Net Debt to EBITDA		 8.83 9.96 10.77 11.50 12.29 32.50 44.81 52.28 99.40 19.35
Long-Term Debt to EBITDA		 9.12 10.19 11.09 11.87 12.71 33.32 45.83 55.90 102.47 20.10
Debt to NOPAT		 14.63 16.91 20.95 67.48 92.19 -43.58 -36.01 -70.84 -33.47 -408.04
Net Debt to NOPAT		 14.17 16.53 20.35 65.35 89.10 -42.50 -35.21 -66.26 -32.47 -392.71
Long-Term Debt to NOPAT		 14.63 16.91 20.95 67.48 92.19 -43.58 -36.01 -70.84 -33.47 -408.04
Noncontrolling Interest Sharing Ratio		 0.04% 0.04% -51.33% 0.04% 0.01% 0.00% 0.03% 0.03% 0.02% 0.03%
Liquidity Ratios		 - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 757 979 264 318 -62 930 2,113 3,004 3,697 4,035
Operating Cash Flow to CapEx		 3,233.06% 1,581.06% 1,020.52% 498.66% 303.81% 401.63% 248.76% 232.03% 320.77% 471.83%
Free Cash Flow to Firm to Interest Expense		 8.59 0.00 0.00 0.00 -0.58 0.00 0.00 29.62 34.80 0.00
Operating Cash Flow to Interest Expense		 2.43 0.00 0.00 0.00 1.48 0.00 0.00 0.35 0.56 0.00
Operating Cash Flow Less CapEx to Interest Expense		 2.35 0.00 0.00 0.00 0.99 0.00 0.00 0.20 0.38 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.06 0.08 0.08 0.07 0.07 0.05 0.04 0.04 0.03 0.06
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 18,309 18,863 18,881 18,552 18,442 17,698 16,803 15,562 14,657 13,682
Invested Capital Turnover		 0.07 0.08 0.08 0.08 0.07 0.05 0.04 0.04 0.03 0.06
Increase / (Decrease) in Invested Capital		 -630 -866 -156 -452 133 -1,165 -2,078 -2,990 -3,786 -4,016
Enterprise Value (EV)		 14,987 15,413 14,399 14,869 12,754 12,491 12,531 11,352 12,454 10,888
Market Capitalization		 5,808 5,378 4,261 4,955 2,936 2,675 2,655 2,586 3,511 2,372
Book Value per Share		 $14.74 $14.37 $14.11 $13.90 $13.84 $12.74 $11.19 $10.32 $9.06 $8.05
Tangible Book Value per Share		 ($5.28) $12.35 $14.11 ($5.96) ($5.75) $12.74 ($7.84) $12.68 $11.43 $8.05
Total Capital		 18,309 18,863 18,881 18,552 18,442 17,698 16,803 15,562 14,657 13,682
Total Debt		 9,476 10,268 10,438 10,238 10,157 10,064 10,099 9,369 9,216 8,848
Total Long-Term Debt		 9,476 10,268 10,438 10,238 10,157 10,064 10,099 9,369 9,216 8,848
Net Debt		 9,177 10,033 10,136 9,914 9,817 9,814 9,874 8,763 8,940 8,516
Capital Expenditures (CapEx)		 6.62 11 13 15 52 34 30 15 18 16
Net Nonoperating Expense (NNE)		 -96 253 75 -92 -46 429 910 334 712 431
Net Nonoperating Obligations (NNO)		 9,476 10,268 10,438 10,238 10,157 10,064 10,099 9,369 9,216 8,848
Total Depreciation and Amortization (D&A)		 89 89 92 372 85 84 81 108 211 71
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.37 ($0.24) $0.05 ($0.07) $0.19 ($1.10) ($1.46) ($0.54) ($1.34) ($0.68)
Adjusted Weighted Average Basic Shares Outstanding		 598.98M 598.63M 598.30M 598.34M 598.44M 598.52M 600.30M 600.06M 600.23M 600.25M
Adjusted Diluted Earnings per Share		 $0.37 ($0.24) $0.05 ($0.07) $0.19 ($1.10) ($1.46) ($0.54) ($1.34) ($0.68)
Adjusted Weighted Average Diluted Shares Outstanding		 599.34M 598.84M 598.31M 598.34M 598.55M 598.52M 600.30M 600.06M 600.23M 600.25M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($0.07) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 598M 598.30M 598.30M 598.40M 599M 599.10M 600.10M 600.20M 600.40M 600.60M
Normalized Net Operating Profit after Tax (NOPAT)		 126 113 108 -134 71 -235 34 14 -89 19
Normalized NOPAT Margin		 47.77% 24.09% 30.91% -39.78% 35.69% 0.00% 12.61% 8.44% -74.29% 4.32%
Pre Tax Income Margin		 91.05% -26.66% 10.44% -56.52% 63.52% 0.00% -318.61% -184.76% -662.21% -91.64%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 1.55 0.00 0.00 0.00 0.73 0.00 0.00 0.20 -1.19 0.00
NOPAT to Interest Expense		 1.43 0.00 0.00 0.00 0.67 0.00 0.00 0.14 -0.84 0.00
EBIT Less CapEx to Interest Expense		 1.48 0.00 0.00 0.00 0.24 0.00 0.00 0.05 -1.37 0.00
NOPAT Less CapEx to Interest Expense		 1.36 0.00 0.00 0.00 0.18 0.00 0.00 -0.01 -1.01 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 55.30% 77.29% 229.13% 964.46% -2,133.72% -110.66% -36.30% -25.70% -13.69% -13.33%
Augmented Payout Ratio		 55.30% 79.27% 229.13% 964.46% -2,133.72% -110.66% -36.30% -25.70% -13.69% -13.33%

Key Financial Trends

Medical Properties Trust reported strong year-over-year growth in Q4 2024, driven by higher revenue and free cash flow, while continuing to narrow its losses and reduce leverage. However, non-operating losses widened, book value per share declined and operating cash flow softened from a year ago.

  • Total revenue climbed 29% year-over-year in Q4 2024 to $439.5 million.
  • Free cash flow to firm surged to $4.04 billion in Q4 2024 versus $0.93 billion a year earlier.
  • Net loss narrowed to $412 million in Q4 2024 from $664 million in Q4 2023.
  • Leverage improved: net debt/EBITDA fell to 19.35× in Q4 2024 from 32.5× a year ago.
  • Valuation looks attractive with EV/FCFF at 2.73×, down from 13.38× in Q4 2023.
  • Dividend yield remained high at 11.6% in Q4 2024, though off from 19.7% a year ago.
  • Adjusted EPS loss improved to –$0.68 in Q4 2024 from –$1.10 in Q4 2023.
  • Nonoperating losses widened to –$430 million in Q4 2024 versus –$324 million a year earlier.
  • Book value per share declined to $8.05 in Q4 2024 from $12.74 in Q4 2023.
  • Operating cash flow fell to $76.7 million in Q4 2024 compared to $135.4 million in Q4 2023.
06/23/25 03:22 PMAI Generated. May Contain Errors.

Frequently Asked Questions About Medical Properties Trust's Financials

When does Medical Properties Trust's financial year end?

According to the most recent income statement we have on file, Medical Properties Trust's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Medical Properties Trust's net income changed over the last 9 years?

Medical Properties Trust's net income appears to be on a downward trend, with a most recent value of -$2.41 billion in 2024, falling from $139.93 million in 2015. The previous period was -$556.09 million in 2023. Check out Medical Properties Trust's forecast to explore projected trends and price targets.

How has Medical Properties Trust's revenue changed over the last 9 years?

Over the last 9 years, Medical Properties Trust's total revenue changed from $441.88 million in 2015 to $995.55 million in 2024, a change of 125.3%.

How much debt does Medical Properties Trust have?

Medical Properties Trust's total liabilities were at $9.46 billion at the end of 2024, a 11.3% decrease from 2023, and a 170.1% increase since 2015.

How much cash does Medical Properties Trust have?

In the past 9 years, Medical Properties Trust's cash and equivalents has ranged from $83.24 million in 2016 to $1.46 billion in 2019, and is currently $332.34 million as of their latest financial filing in 2024.

How has Medical Properties Trust's book value per share changed over the last 9 years?

Over the last 9 years, Medical Properties Trust's book value per share changed from 8.84 in 2015 to 8.05 in 2024, a change of -8.9%.


Related Companies

This page (NYSE:MPW) was last updated on 6/23/2025 by MarketBeat.com Staff
From Our Partners
Your Bank Account Is No Longer Safe
What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...
Priority Gold | Sponsored
Trump’s Exec Order #14154 could be a “Millionaire-Maker”
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...
Paradigm Press | Sponsored
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...
Brownstone Research | Sponsored
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
A new rule goes live in July — and the banks are quietly cashing in
A major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...
American Alternative | Sponsored
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
The IRS Loophole That Lets You Own Gold Tax-Free
What if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...
Advantage Gold | Sponsored